Q3 2024 Lineage Cell Therapeutics Inc Earnings Call Transcript

Nov 14, 2024 / 09:30 PM GMT

Release Date Price: €0.8 (-3.03%)

Transcript 10-Q8-K

Key Points

Positve

Lineage Cell Therapeutics Inc (LCTX) has extended its cash runway to support operations into Q1 2026, indicating strong fiscal discipline.
The company has made significant progress with the FDA regarding the OPC1 dose study, obtaining a clear path to commence enrollment.
Lineage's partnership with Genentech for the Opgen program shows promising signs, with Genentech maintaining and investing in the program despite industry cutbacks.
The company has achieved RMAT designation for its Opgen program, which could provide regulatory advantages.
Lineage is advancing its manufacturing capabilities, aiming to achieve commercial-scale production of allogeneic cell therapies, which could position it as a leader in the field.

Negative

Lineage Cell Therapeutics Inc (LCTX) does not have access to interim data from the ongoing Opgen phase two study, creating uncertainty about the program's progress.
The company is still awaiting FDA review completion for the OPC1 IND amendment, which has been a lengthy process.
There is a lack of clarity on the timeline for potential milestone payments from the Roche and Genentech collaboration.
The company faces challenges in ensuring the purity, potency, and yield necessary for commercial-scale manufacturing.
Lineage's financial results show a net loss of $3 million for the quarter, indicating ongoing financial challenges.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LCTX.A - Lineage Cell Therapeutics Inc
Q3 2024 Lineage Cell Therapeutics Inc Earnings Call
Nov 14, 2024 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the lead cell therapeutics third quarter, 2024 conference call at this time, all participants are in a listen-only mode. An audio webcast of this call is available on the web investor section of lineage website at www dot lineage call dotcom. This call is subject to copyright and is the property of lineage and recordings. Reproductions or transmissions of this call without the express written consent of lineage are strictly prohibited. As a reminder, today's call is being recorded. I would now like to introduce your host for today's call, Ian Ho head of Investor Relations at Te Age, MS Hon. Please go ahead.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.